SPL Stock Overview
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.13 |
52 Week High | AU$0.48 |
52 Week Low | AU$0.10 |
Beta | 0.77 |
1 Month Change | -3.85% |
3 Month Change | -13.79% |
1 Year Change | -72.83% |
3 Year Change | -93.04% |
5 Year Change | -90.35% |
Change since IPO | -80.77% |
Recent News & Updates
Recent updates
Shareholder Returns
SPL | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -3.8% | 3.0% | -1.5% |
1Y | -72.8% | 33.8% | 5.7% |
Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned 31.1% over the past year.
Return vs Market: SPL underperformed the Australian Market which returned 6.1% over the past year.
Price Volatility
SPL volatility | |
---|---|
SPL Average Weekly Movement | 7.7% |
Pharmaceuticals Industry Average Movement | 10.6% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: SPL has not had significant price volatility in the past 3 months.
Volatility Over Time: SPL's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 45 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.
Starpharma Holdings Limited Fundamentals Summary
SPL fundamental statistics | |
---|---|
Market cap | AU$49.44m |
Earnings (TTM) | -AU$8.39m |
Revenue (TTM) | AU$10.52m |
4.7x
P/S Ratio-5.9x
P/E RatioIs SPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPL income statement (TTM) | |
---|---|
Revenue | AU$10.52m |
Cost of Revenue | AU$11.68m |
Gross Profit | -AU$1.16m |
Other Expenses | AU$7.24m |
Earnings | -AU$8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | -11.02% |
Net Profit Margin | -79.79% |
Debt/Equity Ratio | 0% |
How did SPL perform over the long term?
See historical performance and comparison